Imaging Tumorous Methylglyoxal by an Activatable Near-Infrared Fluorescent Probe for Monitoring Glyoxalase 1 Activity.

Imaging Tumorous Methylglyoxal by an Activatable Near-Infrared Fluorescent Probe for Monitoring... The accurate detection of tumorous methylglyoxal (MGO) and its detoxifier glyoxalase 1 (GLO1) in living systems is critical for understanding their roles in tumor initiation and progression. To date, the in situ fluorescence detection of endogenous MGO and GLO1 in tumor has not been reported. Herein we developed a near-infrared (NIR) fluorescent probe MEBTD to specifically detect tumorous MGO. Compared with previously reported MGO fluorescent probes, MEBTD exhibits several distinct advantages, including NIR emission, high selectivity with an MGO detection limit of 18 nM, and a 131-fold off-on ratio. The probe could sense GLO1 activity and monitor the therapeutic effect of GLO1 inhibitors by imaging tumorous MGO in a both a real-time and in situ manner, demonstrating that the biological effect of GLO1 inhibitors is dependent on the GLO1 activity. Furthermore, MEBTD enables the visualization of tumorous MGO induced by GLO1 inhibitors in vivo. To the best of our knowledge, MEBTD is the first NIR fluorescent probe for specifically imaging tumorous MGO in living animals, indicating the promising potential for tumor diagnosis and therapeutic evaluation. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Analytical chemistry Pubmed

Imaging Tumorous Methylglyoxal by an Activatable Near-Infrared Fluorescent Probe for Monitoring Glyoxalase 1 Activity.

Analytical chemistry, Volume 91 (24): 8 – Dec 17, 2019
Preview Only

Imaging Tumorous Methylglyoxal by an Activatable Near-Infrared Fluorescent Probe for Monitoring Glyoxalase 1 Activity.

Analytical chemistry, Volume 91 (24): 8 – Dec 17, 2019

Abstract

The accurate detection of tumorous methylglyoxal (MGO) and its detoxifier glyoxalase 1 (GLO1) in living systems is critical for understanding their roles in tumor initiation and progression. To date, the in situ fluorescence detection of endogenous MGO and GLO1 in tumor has not been reported. Herein we developed a near-infrared (NIR) fluorescent probe MEBTD to specifically detect tumorous MGO. Compared with previously reported MGO fluorescent probes, MEBTD exhibits several distinct advantages, including NIR emission, high selectivity with an MGO detection limit of 18 nM, and a 131-fold off-on ratio. The probe could sense GLO1 activity and monitor the therapeutic effect of GLO1 inhibitors by imaging tumorous MGO in a both a real-time and in situ manner, demonstrating that the biological effect of GLO1 inhibitors is dependent on the GLO1 activity. Furthermore, MEBTD enables the visualization of tumorous MGO induced by GLO1 inhibitors in vivo. To the best of our knowledge, MEBTD is the first NIR fluorescent probe for specifically imaging tumorous MGO in living animals, indicating the promising potential for tumor diagnosis and therapeutic evaluation.
Loading next page...
 
/lp/pubmed/imaging-tumorous-methylglyoxal-by-an-activatable-near-infrared-Mv895Uj2Ch
DOI
10.1021/acs.analchem.9b03600

Abstract

The accurate detection of tumorous methylglyoxal (MGO) and its detoxifier glyoxalase 1 (GLO1) in living systems is critical for understanding their roles in tumor initiation and progression. To date, the in situ fluorescence detection of endogenous MGO and GLO1 in tumor has not been reported. Herein we developed a near-infrared (NIR) fluorescent probe MEBTD to specifically detect tumorous MGO. Compared with previously reported MGO fluorescent probes, MEBTD exhibits several distinct advantages, including NIR emission, high selectivity with an MGO detection limit of 18 nM, and a 131-fold off-on ratio. The probe could sense GLO1 activity and monitor the therapeutic effect of GLO1 inhibitors by imaging tumorous MGO in a both a real-time and in situ manner, demonstrating that the biological effect of GLO1 inhibitors is dependent on the GLO1 activity. Furthermore, MEBTD enables the visualization of tumorous MGO induced by GLO1 inhibitors in vivo. To the best of our knowledge, MEBTD is the first NIR fluorescent probe for specifically imaging tumorous MGO in living animals, indicating the promising potential for tumor diagnosis and therapeutic evaluation.

Journal

Analytical chemistryPubmed

Published: Dec 17, 2019

There are no references for this article.

Sorry, we don’t have permission to share this article on DeepDyve,
but here are related articles that you can start reading right now:

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off